Cancer Immunotherapy Guidelines

Cancer Immunotherapy Guidelines 

• Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma (12 Sept 2021)
• Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer (13 Aug 2021)
• Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer (15 July 2021)
• Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events (25 June 2021)
• Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma (24 Dec 2020)
• Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events (16 Dec 2020)
• The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia (19 Oct 2020)
• The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma (12 July 2020)
• The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC) (20 Dec 2019)
• The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) (15 July 2019)
• The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC) (17 July 2018)
• An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0 (30 May 2018)
  
• The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma (20 Dec 2016)

• JITC collections